This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
In terms of disease incidence without vaccination, there were 20 cases per 100,000 population among high-risk 15 to 19-year-olds (regional area) and 7 cases per 100,000 population among high-risk 20 to 24-year-olds. There were 6 cases per 100,000 population in the general population of 15 to 19-year-olds, and 1.2 cases per 100,000 population in the general population of 20 to 24-year-olds.
Vaccination coverage was 90% for high-school students and 60% for first-year university students.
These data were mainly derived from personal communications based on the 1999 Victorian measles vaccination campaign and 1997 Higher Education Office data.
Measure of benefits used in the economic analysis
The main benefit measures used in the cost-effectiveness analysis were the disability-adjusted life-years (DALYs) and life-years saved (LYS). The disability weights used to calculate the DALYs were derived from published studies. Other benefit measures derived from the decision model were the number of cases of disease averted. The benefit measure used in the cost-benefit analysis was avoided lost earnings due to morbidity and premature mortality from meningitis. These were calculated using the human capital approach, and although this was not explicitly stated as the methodology used by the authors, the approach was consistent with conventional cost-benefit analysis. A 5% discount rate was applied to events occurring after the first year.
Direct costs
A 5% discount rate was applied to the costs incurred after the first year, as the time horizon of the model was 5 years. The unit costs were reported separately from the quantities of resources. Only vaccination costs were included in the economic evaluation. These costs referred to the vaccine itself, vaccine administration (staff, travel and equipment), treating side effects of the vaccine, and campaign promotion. The costs of disease treatment and public health followup costs (arising from training and providing chemoprophylaxis to close contacts) were also included in the analysis to calculate cost-savings. The cost/resource boundary adopted in the analysis reflected the societal perspective of the study. The direct costs were estimated from the point of view of the Department of Human Services (DHS) in Victoria, Australia. The costs and quantities were mainly estimated on the basis of actual data derived from the DHS. The price year was 1999.
